The role of early in vivo toxicity testing in drug discovery toxicology

Expert Opinion on Drug Safety

Volumn 7, Issue 2, 2008, Pages 107-110

  Fielden, Mark R ^a   Kolaja, Kyle L ^a  

^a ROCHE BIOSCIENCE   (United States)

Author keywords

Animal model; Biomarker; Discover toxicology; In vivo; Mechanisms; Predictive

Indexed keywords

ANTIDEPRESSANT AGENT; BIOLOGICAL MARKER; NORADRENALIN TRANSPORTER; RNA DIRECTED DNA POLYMERASE INHIBITOR; THYROID HORMONE;

CARDIOTOXICITY; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; CYTOTOXICITY; DRUG APPROVAL; DRUG INDICATION; DRUG INDUSTRY; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; DRUG TARGETING; DRUG TOLERABILITY; EDITORIAL; HUMAN; IN VIVO STUDY; MITOCHONDRIAL TOXICITY; NONHUMAN; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; THYROID HORMONE SYNTHESIS; TOXICITY TESTING; TOXICOKINETICS; TOXICOLOGY; VIRUS STRAIN;

ANIMALS; DRUG APPROVAL; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; DRUGS, INVESTIGATIONAL; MODELS, ANIMAL; PREDICTIVE VALUE OF TESTS; SPECIES SPECIFICITY; TIME FACTORS; TOXICITY TESTS;

EID: 41349087120     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.7.2.107     Document Type: Editorial

References (18)

1. Gross CJ, Kramer JA. The role of investigative molecular toxicology in early stage drug development. Expert Opin Drug Saf 2003;2:147-59
2. Greaves P, Williams A, Eve M. First dose of potential new medicines to humans: how animals help. Nat Rev Drug Discov 2004;3:226-36
3. Frantz S, Smith A. New drug approvals for 2002. Nat Rev Drug Discov 2003;2:95-6
4. Dimasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ 2003;22:151-85
5. US Food and Drug Administration. Innovation or stagnation? Challenge and opportunity on the critical path to new medical products. Available from: URL: www.fda.gov/oc/initiatives/criticalpath/whitepaper.html [Last accessed 4 February 2008]
6. Olson H, Betton G, Robinson D, et al. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Toxicol Pharmacol 2000;32:56-67
7. Mutlib AE, Gerson RJ, Meunier PC, et al. The species-dependent metabolism of efavirenz produces a nephrotoxic glutathione conjugate in rats. Toxicol Appl Pharmacol 2000;169:102-13
8. Wu KM, Farrelly JG. Preclinical development of new drugs that enhance thyroid hormone metabolism and clearance: inadequacy of using rats as an animal model for predicting human risks in an IND and NDA. Am J Ther 2006;13:141-4
9. Cohen SM, Lawson TA. Rodent bladder tumors do not always predict for humans. Cancer Lett 1995;93:9-16
10. Sasseville VG, Lane JH, Kadambi VJ, et al. Testing paradigm for prediction of development-limiting barriers and human drug toxicity. Chem Biol Interact 2004; 150:9-25
11. Kramer JA, Sagartz JE, Morrsi DL. The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates. Nat Rev Drug Discov 2007;6:636-49
12. Searfoss GH, Jordan WH, Calligaro DO, et al. Adipsin, a biomarker of gastrointestinal toxicity mediated by a functional gamma-secretase inhibitor. J Biol Chem 2003;278:46107-16
13. Sawada H, Takami K, Asahi S. A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system. Toxicol Sci 2005;83:282-92
14. Moyle G. Mitochondrial toxicity: myths and facts. J HIV Ther 2004;9:45-7
15. Hutzler M, Messing DM, Wienkers LC. Predicting drug-drug interactions in drug discovery: where are we now and where are we going? Curr Opin Drug Discov Dev 2005;8:51-8
16. Force T, Krause DS, Van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 2007;7:332-44
17. Doss GA, Baillie TA. Addressing metabolic activation as an integral component of drug design. Drug Metab Rev 2006;38:641-9
18. Critical Path Institute, Tucson, AZ. Available from: URL: www.c-path.org [Last accessed 4 February 2008]